For example patients with advanced cancers and BRAF mutations have less soft tissue, retroperitoneal, lung metastases and more brain metastases.[17] In colorectal cancer, BRAF mutations predicted poor outcome and KRAS mutations were associated with lung metastases.[13, 18] We investigated characteristics and outcomes of patients with advanced cancers with and without PIK3CA mutations. This evidence concerns the gene KRAS and cancer.